Placebo is identical to IMP but with no active substance.
Sponsors
Immunovant Sciences GmbH
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Generalized Myasthenia Gravis (gMG)Graves’ DiseaseGrave’s DiseaseThyroid Eye DiseaseThyroid Eye Disease (TED)
Phase 2
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SuspendedCTIS2024-512646-42-00
Start: 2023-06-27Target: 178Updated: 2025-10-08
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
RecruitingCTIS2024-516020-33-00
Start: 2025-06-26Target: 158Updated: 2025-12-08
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
RecruitingCTIS2025-521920-31-00
Start: 2025-11-21Target: 110Updated: 2025-11-05
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingCTIS2024-517614-14-00
Start: 2025-11-28Target: 79Updated: 2026-01-16
Phase 3
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Active, not recruitingCTIS2024-512649-18-00
Start: 2023-06-05Target: 75Updated: 2025-12-18
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)
Active, not recruitingCTIS2024-512258-91-00
Start: 2023-02-03Target: 152Updated: 2025-03-31
IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
CompletedCTIS2024-512648-45-00
Start: 2023-11-30End: 2025-10-30Target: 36Updated: 2025-08-14